Daiichi Sankyo (DSNKY) News Today → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free DSNKY Stock Alerts $30.29 +0.17 (+0.56%) (As of 04/23/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMHRA authorises Daiichi Sankyo quizartinib for AML for marketingmsn.com - March 13 at 12:17 AMPfizer, Gilead, Roche seen benefitting the most from antibody-drug conjugatesmsn.com - March 2 at 2:32 PMDaiichi Sankyo Co. Ltd. ADRwsj.com - February 25 at 8:45 AMDatopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancerfinance.yahoo.com - February 19 at 6:01 AMDaiichi Sankyo Co Ltd 4568morningstar.com - February 16 at 8:07 PMDaiichi invests 1 billion eur near Munich to make precision cancer drugsnews.yahoo.com - February 16 at 10:07 AMDaiichi invests 1 bln eur near Munich to make precision cancer drugsfinance.yahoo.com - February 16 at 10:07 AMQ4 2023 Merck & Co Inc Earnings Callfinance.yahoo.com - February 2 at 1:56 AMWhat's Going On With Pfizer Stock Today?msn.com - January 25 at 7:09 PMUS Patent Office Invalidates Seagen Patent In Daiichi Sankyo Dispute - Quick Factsmarkets.businessinsider.com - January 17 at 8:17 AMU.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagenfinance.yahoo.com - January 17 at 1:34 AMEsperion Therapeutics, Daiichi Sankyo Europe Reach $125M Payment Agreement Over Commercial Litigationmarketwatch.com - January 3 at 12:08 PMWhy Pharmaceutical Company Esperion Therapeutics Shares Are Diving Todaymsn.com - January 3 at 12:08 PMMerck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecanmarkets.businessinsider.com - December 22 at 1:10 PMPatritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancerfinance.yahoo.com - December 22 at 8:10 AMDaiichi Sankyo Co., - ADR (DSNKY) Price Target Increased by 8.80% to 38.57msn.com - December 17 at 5:48 PMDepixus Announces Strategic Collaboration With Daiichi Sankyo to Use MAGNA™ Technology to Accelerate RNA-targeted Drug Discoverybusinesswire.com - December 12 at 7:30 AM300,000 New Cases: The Role of Biotech in Addressing Rising Breast Cancer Ratesbaystreet.ca - December 1 at 12:24 PMDaiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASHbusinesswire.com - December 1 at 12:24 PMJapan panel recommends approval of updated Daiichi Sankyo COVID shot- Kyodofinance.yahoo.com - November 27 at 8:04 AMDaiichi Sankyo Co., Ltd. (4568)investing.com - October 31 at 2:39 PMMerck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?finance.yahoo.com - October 31 at 2:39 PMMerck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Salesfinance.yahoo.com - October 26 at 2:23 PM‘Guided Missile Drugs’ Could Be Big Pharma’s Secret Weaponfinance.yahoo.com - October 26 at 9:23 AMMerck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo Dealbloomberg.com - October 23 at 8:52 AMRaludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trialfinance.yahoo.com - October 22 at 8:38 AMNikkei Falls 0.5%, Dragged by Electronics, Retail Stocksfinance.yahoo.com - October 20 at 9:07 AMMerck teams up with Daiichi Sankyo on antibody drug conjugate collaborationnews.yahoo.com - October 20 at 12:04 AMJapan's Daiichi Sankyo, Merck Announce $22bn Cancer Drug Dealbarrons.com - October 20 at 12:04 AMMerck signs $5.5 bln deal with Daiichi for cancer therapy developmentreuters.com - October 20 at 12:04 AMExperimental Drug Wards Off Both Lung and Breast Cancer Progression in Trialsfinance.yahoo.com - October 18 at 8:57 AMDaiichi Sankyo Showcases Progress in Developing New Standards of Care for Patients with Industry-Leading DXd ADC Portfolio Across Multiple Cancers at ESMOfinance.yahoo.com - October 16 at 9:44 AMNikkei Falls 1.1%, Dragged by Pharma, Electronics Stocksfinance.yahoo.com - September 26 at 7:54 AMU.S. Stocks Open Lower After S&P 500 Logs Three Straight Weeks Of Lossesfinance.yahoo.com - September 25 at 12:26 PMDaiichi Sankyo Leads Japan Pharma Stocks Higher on Cancer Drugfinance.yahoo.com - September 25 at 7:22 AMStock Market Today: Bond Yields Climb Toward 4.5%finance.yahoo.com - September 25 at 7:22 AMNikkei Flat, Supported by Electronics, Pharma Stocksfinance.yahoo.com - September 24 at 8:45 PMDatopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trialfinance.yahoo.com - September 22 at 10:17 AMAstraZeneca Surges To 50-Day Line After Breast Cancer Drug Tops Chemofinance.yahoo.com - September 22 at 10:17 AMAstraZeneca and Daiichi Sankyo's Enhertu recommended for approvallse.co.uk - September 15 at 2:21 PMUPDATE 1-EU regulator backs AstraZeneca and Daiichi's lung cancer drugfinance.yahoo.com - September 15 at 2:21 PMDaiichi to File for US Approval of New Lung Cancer Drug by Marchbloomberg.com - September 12 at 2:07 AMPatritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trialfinance.yahoo.com - September 10 at 5:33 AMIfinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trialfinance.yahoo.com - September 10 at 5:33 AMDS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancersfinance.yahoo.com - September 7 at 7:09 PMThe Fukushima Daiichi nuclear power plant has begun releasing its first batch of treated radioactive water into the seaabcnews.go.com - August 24 at 5:51 PMDaiichi Sankyo and AstraZeneca's Enhertu wins new approval in Japanlse.co.uk - August 23 at 3:48 AMDaiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients with Lung Cancer with Data Across DXd ADC Portfolio at WCLCfinance.yahoo.com - August 16 at 3:50 PMVANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AMLfinance.yahoo.com - August 9 at 8:08 AMENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trialfinance.yahoo.com - July 27 at 2:28 AM Get Daiichi Sankyo News Delivered to You Automatically Sign up to receive the latest news and ratings for DSNKY and its competitors with MarketBeat's FREE daily newsletter. Email Address This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry DSNKY Media Mentions By Week DSNKY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DSNKY News Sentiment▼0.000.43▲Average Medical News Sentiment DSNKY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DSNKY Articles This Week▼01▲DSNKY Articles Average Week Get Daiichi Sankyo News Delivered to You Automatically Sign up to receive the latest news and ratings for DSNKY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AstraZeneca News Today Cosmo Pharmaceuticals News Today JCR Pharmaceuticals News Today Kyowa Kirin News Today Mayne Pharma Group News Today Ono Pharmaceutical News Today Ono Pharmaceutical News Today Otsuka News Today Roche News Today Sanofi News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:DSNKY) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daiichi Sankyo Company, Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
